Scholarlink

Introduction <p>Caspofungin pharmacokinetics may be altered in critically ill patients. In vitro studies suggest significant drug adsorption with polyacrylonitrile (PAN) membranes during continuous renal replacement therapy (CRRT).</p> Methods <p>This study retrospectively analyzed 66 plasma caspofungin concentrations (pCAS<sub>conc</sub>) from 35 ICU patients between 2021 and 2024, comparing those on PAN-CRRT (<i>n</i>&#xa0;=&#xa0;19) versus those without (<i>n</i>&#xa0;=&#xa0;47).</p> Results <p>Caspofungin is mainly prescribed for candidemia (40%) and invasive <i>Candida</i> infections (25.7%). Median pCAS<sub>conc</sub> at 12&#xa0;h was similar between groups, but at 18 and 24&#xa0;h, it was significantly higher in the PAN-CRRT group [5.3 (4.1–6.9) vs. 3.3 (1.9–3.7) mg/L, <i>p</i>&#xa0;=&#xa0;0.04 and 5.3 (3.9–5.8) vs. 3.1 (2.5–4.5) mg/L, <i>p</i>&#xa0;=&#xa0;0.01, respectively]. ECMO use was more frequent in PAN-CRRT patients (75% vs. 21.7%, <i>p</i>&#xa0;=&#xa0;0.01). Persistent candidemia occurred in three patients (one in PAN-CRRT, two in non-PAN-CRRT).</p> Conclusion <p>This study found no evidence of caspofungin depletion with PAN-CRRT, warranting further research on clinical outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of Continuous Renal Replacement Therapy with Polyacrylonitrile-Derived Filter on Caspofungin Concentration: A Retrospective Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月5日

查看全文
  • Romain Arrestier,
  • Claire Pressiat,
  • Laura Bouabdallah,
  • Paul Masi,
  • Nicolas Mongardon,
  • Anne Hulin,
  • Armand Mekontso Dessap,
  • Keyvan Razazi

摘要

Introduction

Caspofungin pharmacokinetics may be altered in critically ill patients. In vitro studies suggest significant drug adsorption with polyacrylonitrile (PAN) membranes during continuous renal replacement therapy (CRRT).

Methods

This study retrospectively analyzed 66 plasma caspofungin concentrations (pCASconc) from 35 ICU patients between 2021 and 2024, comparing those on PAN-CRRT (n = 19) versus those without (n = 47).

Results

Caspofungin is mainly prescribed for candidemia (40%) and invasive Candida infections (25.7%). Median pCASconc at 12 h was similar between groups, but at 18 and 24 h, it was significantly higher in the PAN-CRRT group [5.3 (4.1–6.9) vs. 3.3 (1.9–3.7) mg/L, p = 0.04 and 5.3 (3.9–5.8) vs. 3.1 (2.5–4.5) mg/L, p = 0.01, respectively]. ECMO use was more frequent in PAN-CRRT patients (75% vs. 21.7%, p = 0.01). Persistent candidemia occurred in three patients (one in PAN-CRRT, two in non-PAN-CRRT).

Conclusion

This study found no evidence of caspofungin depletion with PAN-CRRT, warranting further research on clinical outcomes.